Cancer PROGRAMS

QUALITY PROGRAMS of the AMERICAN COLLEGE OF SURGEONS

NATIONAL CANCER DATABASE

Tips & Tricks for Rapid Cancer Reporting System (RCRS)

October 1, 2021

Susanne Kessler, MSM, RHIT, CTR
Cindy Traylor-Richards, CTR

American College of Surgeons
Inspiring Quality: Highest Standards, Better Outcomes
100+years

Disclosures

- None

© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Objectives

- Discuss RCRS User Access
- Demonstrate Uploads & Reports
- Explain Tips for Quicker Navigation
- Understanding Your Data

© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Expected Outcomes

- Increased knowledge of
  - Functionality
  - Data availability

© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

RCRS Library

- User Guide
- Measure Specifications
- Videos
- Notifications



© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Overview of Access

- Must be listed on FINs Datalinks Manage Staff Contacts
- Program must add/remove users
- One email address for user even when multiple FINs
- One user ID

© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Dashboard



© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Navigation Panel



© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Upload



© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Upload History Report



© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Submission Detail Report



© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Notifications



© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Operational Reports



© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Alerts



© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Alert Status

Cases are based on # of Days Until Expected Administration of Non-Surgical Therapy

	Alert Status – Based on the # of Days Until Expected Administration of non-Surgical Therapy				
Measure	Low (white/cream)	Moderate (yellow)	Almost Critical (orange)	Critical (red)	Non-concordant (dark red)
BCSRT	≥241	240-181	180-91	≤90	Past due
MAC	≥91	90-61	60-31	≤30	Past due
HT	≥211	210-151	150-76	≤75	Past due
MASTRT	≥241	240-181	180-91	≤90	Past due
ACT	≥91	90-61	60-31	≤30	Past due
12RLN	No Alerts for Colon 12 RLNs				

© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Alert Status

Cases are based on # of Days Until Expected Administration of Non-Surgical Therapy

	Alert Status – Based on the # of Days Until Expected Administration of non-Surgical Therapy				
Measure	Low (white/cream)	Moderate (yellow)	Almost Critical (orange)	Critical (red)	Non-concordant (dark red)
BCSRT	≥241	240-181	180-91	≤90	Past due
MAC	≥91	90-61	60-31	≤30	Past due
HT	≥211	210-151	150-76	≤75	Past due
MASTRT	≥241	240-181	180-91	≤90	Past due
ACT	≥91	90-61	60-31	≤30	Past due
12RLN	No Alerts for Colon 12 RLNs				

© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Alerts Reports



© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Alerts Reports

Reporting Facility	
Facility ID	
Archive FIN	
Source ID	IQVIA
Acc #	202000223
Seq #	00
Measure Name	HT
Measure Status	S
Measure Description	HT status unknown, administration expected within 365 days ...
Days Remaining	-3
EXCLUSION	
Date of Diagnosis	2020/07/23
Sex	2
Age	54
Class of Case	14
Primary Site	C502
Histology Type ICD-O-3	8500
Behavior Code ICD-O-3	3
CS Tumor Size	
Tumor Size Summary	013
CS Site-Specific Factor 1	
ER Sum	1
ER %	095%
CS Site-Specific Factor 2	
PR Sum	1
PR %	090%
CS Site-Specific Factor 15	
HER2	0
CS Site-Specific Factor 6	
CRM	
CS Site-Specific Factor 25	
Scehma Disc 1	
Grade	
Grade Clin	2
TNM Edition Number	08
TNM Clin T	

© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Alerts Reports

RX Date Radiation	2020/10/26
RX Date Rad Ended	2020/12/17
Rad--Location of RX	1
Rad--Regional RX Modality	
ph1 RT MOD	02
ph1 BM TCHQ	01
Rad--Boost RX Modality	
Rad--Treatment Volume	
ph1 RT VOL	40
Reason for No Radiation	0
RX Summ--Hormone	88
RX Date Hormone	
RX Summ--BRM	00
Rx Date BRM	
Rx Date Systemic	
VITAL ST	1
Date First Contact	2020/07/23
Date Last Contact	2021/04/20
Update	2021/06/23 10:41:11 AM

© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Alerts Reports

File

Case Identification	
MRN #	
Patient Name	

Patient Characteristics	
Date of Birth / Age	1965/12/12 / 054
Gender	2

Tumor Characteristics	
Diagnosis Date	2020/07/23
Primary Site	C502
Histology	8500
Surg Diag Staging Proc	02
Staging proc date	2020/07/23
Behavior	3
Nodes Examined	14
Nodes Positive	01
Tumor Size / Tumor Size Summary	/ 013
ER Status	1
PR Status	1
ER %	095%

Case Identification	
Accession Number	202000223
Sequence #	00
Class of Case	14
Last Contact Date / Vital Status	2021/04/20 / 1
Facility	
Recorded Last Update	2021-06-23
Source ID	IQVIA

AJCC Clinical Stage Group	
Clinical Stage Group	1B
Clinical T	cT1c
Clinical N	cN1
Clinical M	cM0
AJCC Pathologic Stage Group	
Path Stage Group	1A
Path T	pT1c
Path N	pN1a
Path M	cM0

Treatment Summary			
Surgery Date	2020/09/02	Date of most definitive Surgery	2020/09/02
Surgery	22	Surgery at this facility	22
Radiation Reg Modality		Phase I Modality	02
		Phase I Beam Techng	01
Radiation Volume		Phase I Volume	40
Radiation Date	2020/10/26	Reason No Radiation	0
Hormone	88	Hormone Date	
Chemotherapy	00	Chemo Date	
Immunotherapy	00	BRM Date	

© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Case Log Reports



© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Quality Measures



© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Quality Measures



© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Quality Measures

- **Dark green** represent data where upper confidence interval is equal to or greater than the benchmark. The dark green shade represents cases for years that have been locked, starting from current year – 3 (example, current year = 2020 so 2017 and prior will have darker green).
- **Dark red** represent data where upper confidence interval is less than the benchmark. The dark red shade represents cases for years that have been locked, which is current year – 3 (example, current year = 2020 so 2017 and prior will have dark red)
- **Light green** represents data where upper confidence interval is equal to or greater than the benchmark. The light green shade represents cases for years that are still open and could potentially change, which is current year – 2 (example, current year = 2020 so 2020, 2019 and 2018 will have light green). Light green will change to dark green only when it meets current year – 3 condition, for example if 2018 is light green in 2020, it will change to dark green when we get to 2021.
- **Light red** represents data where upper confidence interval is equal is less than the benchmark. The light red shade represents cases for years that have are still open and could potentially change, which is current year – 2 (example, current year = 2020 so 2020, 2019 and 2018 will have light red). Light red will change to dark red only when it meets current year – 3 condition, for example if 2018 is light green in 2020, it will change to dark green when we get to 2021.

© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Quality Measures



Click on the tab to Open Rolling Year EPRs

© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Quality Measures



© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Rolling Year EPR

Primary Sites	Measure	Treatment Expectation Timeframe (# months)	# of Months Case is Included in Calculations
Breast • HT • BCSRT • MASTRT	Hormone Therapy Radiation Following BCS Radiation following mast with 4 + LNs	12 months	24 months from Diagnosis Date: 12 months to receive treatment + 12 months [365 days] included in the YTD date range
Breast • ACT Colon • MAC	Adjuvant Chemotherapy	4 months	16 months from Diagnosis Date: 4 months to receive treatment + 12 months [365 days] included in the YTD date range
Colon • 12 RLN Gastric • 15 RLN	Removal & examination of regional lymph nodes	0	12 months from Diagnosis Date: 0 months to receive treatment + 12 months [365 days] included in the YTD date range
Lung • LCT • LNoSurg	Chemotherapy Surgery not 1st course tx for cN2 M0 lung cases	0	12 months from Diagnosis Date: 0 months to receive treatment + 12 months [365 days] included in the YTD date range
Rectal • RECRTCT	Chemotherapy and radiation	0	12 months from Diagnosis Date: 0 months to receive treatment + 12 months [365 days] included in the YTD date range
Breast • nBx	Needle bx to primary site	0	12 months from Diagnosis Date: 0 months to receive treatment + 12 months [365 days] included in the YTD date range

© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Quality Measures Reports

Case Detail Report

ph1 BM TCHQ	00
Rad--Boost RX Modality	
Rad--Treatment Volume	
ph1 RT VOL	00
Reason for No Radiation	1
RX Summ--Hormone	88
RX Date Hormone	
RX Summ--BRM	00
Rx Date BRM	
Rx Date Systemic	
VITAL ST	1
Date First Contact	2021/04/26
Date Last Contact	2021/05/21
Update	2021/06/3 11:08:14 PM

Treatment Summary

Case Identification	
Accession Number	
Sequence #	00
Class of Case	14
Last Contact Date / Vital Status	2021/05/21 / 1
Facility	
Recorded Last Update	2021-06-03

AJCC Clinical Stage Group	
Clinical Stage Group	2A
Clinical T	cT2

© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Comparison Report



© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Comparison Report



Age at Diagnosis	All CoC Programs PR/EPR (%)	All CoC Programs Distinct_Cases	All CoC Programs CI (%)	My Facility (PR/EPR (%)	My Facility (Distinct_Cases
0 to 17		201	%-%		
18 to 39	96.39%	3211	95.23%-97.55%	100.00%	9
40 to 49	96.86%	6521	96.21%-97.51%	90.91%	36
50 to 59	94.17%	15447	93.62%-94.71%	100.00%	85
60 to 69	93.35%	21560	92.88%-93.82%	95.74%	143
70 to 79	93.77%	21429	93.34%-94.21%	94.59%	108
80 and over	93.82%	17152	93.34%-94.30%	97.37%	59
Unknown		10	%-%		

© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Export



© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Take Away Points

- Why No Cases in Alerts ?
  - Abstracting timeliness
  - Process of coding pending treatment
  - Review cases submitted to RCRS

© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Take Away Points

- Alerts/QMs Not Updating
- Check date of last upload against date the data was last uploaded
  - Was this case included in the upload?
- Uploaded cases must process
  - ~72 hrs after submission to reflect changes
  - Additional time may be needed during heavy submission times
    - End of month
    - Call for Data open time window
- Are there Duplicates
  - Check Case Log

© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Take Away Points

- ER/PR negative
  - ER/PR Summary coded to 0 (Negative)
  - Case showing on breast HT measure

- Review Treatment Summary/Review Details link

- Check data item ER/PR Percent Positive or Range
    - If % is coded to a positive % (001) then eligible

© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Take Away Points

14	Hormone Receptor Positive	CS Site Specific Factor 1 (ER - Estrogen Receptor)	***For Dx Year ≤2017:*** Estrogen Receptor (*ssf1)* = 10, 30 ***OR*** Progesterone Receptor (*ssf2)* = 10, 30
		CS Site Specific Factor 2 (PR - Progesterone Receptor)	
		Estrogen Receptor Percent Positive or Range	***For Dx Year ≥2018:*** ER Percent Positive or Range = 001-100, R10-R99 ***OR*** PR Percent Positive or Range = 001-100, R10-R99
		Progesterone Receptor Percent Positive or Range	

Note: *It is assumed that if a patient received neo-adjuvant chemo/BRM and they are ER/PR+ they should receive hormone therapy independent of tumor size.

24

HT – Breast measure: Tamoxifen or third generation aromatase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0 or Stage IB -Stage III hormone receptor positive breast cancer

Copyright 2020 American College of Surgeons, Commission on Cancer

© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Take Away Points

- Incomplete Case
  - Incomplete Tumor Characteristics
    - Incomplete staging

- Suspense Case
  - Pending receipt of or decision for adjuvant tx
  - Does not apply to BCSRT measure

© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Take Away Points

- Changing view
  - Click, hold, and drag
  - Maximize: Hover mouse in right corner of blue banner for outward arrows
  - Minimize: Hover mouse in middle of blue banner for inward arrows

© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Contact Information

Questions regarding data:

NCDB@facs.org

Questions regarding RCRS functionality:

ACSTechSupport@iqvia.com

© American College of Surgeons 2021—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.